NASDAQ · CORZZ

Core Scientific, Inc.. Tranche 2

$20.51 -$2.16 (-9.53%) 1D Market open

Key Metrics

$7.45B
Market cap
P/E · TTM
$35.72M
Revenue · TTM
−$923.44M
Net income
EPS · TTM $-2.54
Dividend yield
Free cash flow
Beta · 1Y 2.27
EBITDA · TTM
Gross margin 61.3%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    From its Jun 3 high, the share price fell 30%.

    Peak close $29.10 on Jun 3; trough close $20.51 on Jul 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -30%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 9
    The stock moved +11.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 9
  • Feb 6
    The stock moved +13.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value$8.50B
Shares outstanding
52-wk range$12.55 – $30.45
Avg volume · 20D146.5K
Net cash −$1.05B
Book value / share$-3.59
IndustryFinance Services
ExchangeNASDAQ
About Core Scientific, Inc.. Tranche 2
IPO dateJan 24, 2024
Employees325

Core Scientific Inc is engaged in designing, building, and operating digital infrastructure for high-density colocation services and digital asset mining.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S208.62
P/FCF
EV/EBITDA
EV/Sales238.03
Graham №

Profitability

Gross 61.3%
Operating -2,584.2%
Net -2,585.3%
FCF
ROE / ROIC 82.1% · —

Financial Health

Current ratio0.55
Quick ratio
Debt / equity-1.57
Debt / EBITDA
Net cash −$1.05B
Working capital−$1.21B

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

-2.5
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings